IGF1R Contributes to Cell Proliferation in
GSK1904529A
adaptor protein
anaplastic lymphoma kinase
linsitinib
lorlatinib
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
25 Aug 2023
25 Aug 2023
Historique:
received:
17
06
2023
revised:
15
08
2023
accepted:
23
08
2023
medline:
9
9
2023
pubmed:
9
9
2023
entrez:
9
9
2023
Statut:
epublish
Résumé
Aberrant activation of anaplastic lymphoma kinase (ALK) by activating point mutation or amplification drives 5-12% of neuroblastoma (NB). Previous work has identified the involvement of the insulin-like growth factor 1 receptor (IGF1R) receptor tyrosine kinase (RTK) in a wide range of cancers. We show here that many NB cell lines exhibit IGF1R activity, and that IGF1R inhibition led to decreased cell proliferation to varying degrees in ALK-driven NB cells. Furthermore, combined inhibition of ALK and IGF1R resulted in synergistic anti-proliferation effects, in particular in
Identifiants
pubmed: 37686528
pii: cancers15174252
doi: 10.3390/cancers15174252
pmc: PMC10563084
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Barncancerfonden
ID : TJ2016-0088; PR2016-0011; PR2019-0118; PR2022-0029; PR2021-0027
Organisme : National Natural Science Foundation of China
ID : 32170719
Organisme : Swedish Cancer Society
ID : CAN21/1549; CAN21/1525
Organisme : Swedish Research Council
ID : 2019-03914; 2021-1192
Organisme : Swedish Foundation for Strategic Research
ID : RB13-0204
Organisme : Göran Gustafsson Foundation
ID : RHP2016
Organisme : Knut and Alice Wallenberg Foundation
ID : KAW 2018.0057
Références
Nature. 2008 Oct 16;455(7215):930-5
pubmed: 18724359
Cancers (Basel). 2021 Apr 15;13(8):
pubmed: 33921066
Clin Cancer Res. 2009 May 15;15(10):3244-50
pubmed: 19417027
Front Oncol. 2015 May 12;5:111
pubmed: 26029667
Cold Spring Harb Mol Case Stud. 2018 Aug 1;4(4):
pubmed: 29907598
Cancer Res. 2010 Jan 15;70(2):440-6
pubmed: 20068163
Biochem J. 2010 Sep 15;430(3):425-37
pubmed: 20632993
Cancer Res. 1997 Dec 1;57(23):5399-405
pubmed: 9393766
Front Oncol. 2019 Jul 05;9:579
pubmed: 31334113
Nat Commun. 2019 Oct 8;10(1):4567
pubmed: 31594955
J Clin Oncol. 2014 Sep 1;32(25):2727-34
pubmed: 25071110
J Mol Endocrinol. 2018 Jul;61(1):T69-T86
pubmed: 29535161
Elife. 2015 Sep 29;4:e09811
pubmed: 26418745
Sci Signal. 2018 Nov 20;11(557):
pubmed: 30459281
Lancet Oncol. 2015 Apr;16(4):426-35
pubmed: 25795408
Cancers (Basel). 2023 Feb 17;15(4):
pubmed: 36831629
Proc Natl Acad Sci U S A. 2015 Dec 29;112(52):15862-7
pubmed: 26630010
Mol Cancer. 2022 Jun 10;21(1):126
pubmed: 35689207
PLoS One. 2012;7(10):e47109
pubmed: 23056595
EMBO J. 2021 Feb 1;40(3):e105784
pubmed: 33411331
Endocr Relat Cancer. 2016 Nov;23(11):R513-R536
pubmed: 27733416
Oncogene. 2012 Dec 13;31(50):5193-200
pubmed: 22286764
Cell Rep. 2020 Sep 22;32(12):108171
pubmed: 32966799
Dis Model Mech. 2016 Sep 1;9(9):941-52
pubmed: 27483357
Oncogene. 2018 Mar;37(11):1417-1429
pubmed: 29321660
Cold Spring Harb Mol Case Stud. 2021 Aug 2;7(4):
pubmed: 34210658
Nature. 2008 Oct 16;455(7215):975-8
pubmed: 18923525
Nature. 2008 Oct 16;455(7215):971-4
pubmed: 18923524
Cancer Cell. 2012 Jul 10;22(1):117-30
pubmed: 22789543
Clin Cancer Res. 2016 Feb 15;22(4):948-60
pubmed: 26438783
Cancer Discov. 2022 Dec 2;12(12):2800-2819
pubmed: 36108156
Proc Natl Acad Sci U S A. 2018 Jan 23;115(4):E630-E638
pubmed: 29317532
Br J Cancer. 2023 Apr;128(8):1559-1571
pubmed: 36807339
Cancer Discov. 2016 Jan;6(1):96-107
pubmed: 26554404
Cancer Lett. 2017 Aug 1;400:61-68
pubmed: 28455243
Future Med Chem. 2009 Sep;1(6):1153-71
pubmed: 21425998
Sci Rep. 2019 Feb 18;9(1):2199
pubmed: 30778092
PLoS One. 2014 Apr 23;9(4):e95628
pubmed: 24759734
Nat Struct Biol. 2001 Dec;8(12):1058-63
pubmed: 11694888
Oncotarget. 2014 Sep 30;5(18):8737-49
pubmed: 25228590
APMIS. 2019 May;127(5):288-302
pubmed: 30803032
Pediatr Blood Cancer. 2018 Jul;65(7):e27055
pubmed: 29603581
J Mol Biol. 2021 Sep 17;433(19):167158
pubmed: 34273398
Clin Cancer Res. 2009 May 1;15(9):3058-67
pubmed: 19383820
Biochem J. 2008 Dec 1;416(2):153-9
pubmed: 18990089
Cell. 2017 Mar 9;168(6):960-976
pubmed: 28283069
Sci Signal. 2018 Nov 20;11(557):
pubmed: 30459283
J Clin Oncol. 2021 Oct 20;39(30):3377-3390
pubmed: 34115544
Oncotarget. 2016 May 17;7(20):29011-22
pubmed: 27049722
Expert Opin Ther Targets. 2012 Jan;16(1):33-48
pubmed: 22239439
Nature. 2008 Oct 16;455(7215):967-70
pubmed: 18923523
Oncogene. 2001 Oct 1;20(44):6270-2
pubmed: 11607828
Clin Cancer Res. 2017 Jun 1;23(11):2856-2868
pubmed: 27986745
JCO Precis Oncol. 2022 Jan;6:e2100271
pubmed: 35085006
Mol Cell Endocrinol. 2021 May 1;527:111213
pubmed: 33607269
Clin Cancer Res. 2016 Jun 15;22(12):2897-907
pubmed: 26831715
Clin Cancer Res. 2023 Apr 3;29(7):1317-1331
pubmed: 36602782
Cancer Res. 2006 Aug 15;66(16):8139-46
pubmed: 16912192
Lancet Oncol. 2013 May;14(6):472-80
pubmed: 23598171
Cancer Cell. 2014 Nov 10;26(5):682-94
pubmed: 25517749
Nat Rev Dis Primers. 2016 Nov 10;2:16078
pubmed: 27830764
Clin Cancer Res. 2015 Feb 15;21(4):701-11
pubmed: 25212606
Sci Signal. 2014 Oct 28;7(349):ra102
pubmed: 25351247
Clin Cancer Res. 2020 Apr 15;26(8):1837-1845
pubmed: 31792037
Clin Cancer Res. 2015 Nov 1;21(21):4913-21
pubmed: 26059187
Nat Rev Cancer. 2013 Oct;13(10):685-700
pubmed: 24060861
Nat Med. 2023 May;29(5):1092-1102
pubmed: 37012551
Clin Cancer Res. 2021 Jul 1;27(13):3543-3548
pubmed: 33568345
PLoS One. 2013 Dec 11;8(12):e82513
pubmed: 24349301
Biochem J. 2009 May 27;420(3):345-61
pubmed: 19459784
Leuk Lymphoma. 2021 Jul;62(7):1721-1729
pubmed: 33509009
Ann Oncol. 2016 Sep;27 Suppl 3:iii4-iii15
pubmed: 27573755
Nature. 2019 Aug;572(7771):676-680
pubmed: 31391581
Clin Cancer Res. 2010 Sep 1;16(17):4353-62
pubmed: 20719933
Lancet Oncol. 2021 Dec;22(12):1764-1776
pubmed: 34780709
Nat Commun. 2021 Nov 24;12(1):6813
pubmed: 34819497